Novo Nordisk’s next-gen obesity drug stumbles in comparison study
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Novo Nordisk's next-generation obesity drug has failed to match a rival drug from Eli Lilly in a comparison study. The study, known as the CagriSema trial, has reportedly dealt a blow to Novo Nordisk's efforts in the obesity drug market. The outcome of the trial has led to a significant decline in Novo Nordisk's shares.
Full coverage
1
BioPharma Dive·Feb 232
Reuters·Feb 233
CNBC·Feb 234
WSJ·Feb 235
Bloomberg.com·Feb 236
Yahoo! Finance Canada·Feb 237
STAT·Feb 238
Global Banking & Finance Review·Feb 23